HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Orally Active Epoxyeicosatrienoic Acid Analogs.

Abstract
Biologically active epoxyeicosatrienoic acid (EET) regioisomers are synthesized from arachidonic acid by cytochrome P450 epoxygenases of endothelial, myocardial, and renal tubular cells. EETs relax vascular smooth muscle and decrease inflammatory cell adhesion and cytokine release. Renal EETs promote sodium excretion and vasodilation to decrease hypertension. Cardiac EETs reduce infarct size after ischemia-reperfusion injury and decrease fibrosis and inflammation in heart failure. In diabetes, EETs improve insulin sensitivity, increase glucose tolerance, and reduce the renal injury. These actions of EETs emphasize their therapeutic potential. To minimize metabolic inactivation, 14,15-EET agonist analogs with stable epoxide bioisosteres and carboxyl surrogates were developed. In preclinical rat models, a subset of agonist analogs, termed EET-A, EET-B, and EET-C22, are orally active with good pharmacokinetic properties. These orally active EET agonists lower blood pressure and reduce cardiac and renal injury in spontaneous and angiotensin hypertension. Other beneficial cardiovascular actions include improved endothelial function and cardiac antiremodeling actions. In rats, EET analogs effectively combat acute and chronic kidney disease including drug- and radiation-induced kidney damage, hypertension and cardiorenal syndrome kidney damage, and metabolic syndrome and diabetes nephropathy. The compelling preclinical efficacy supports the prospect of advancing EET analogs to human clinical trials for kidney and cardiovascular diseases.
AuthorsWilliam B Campbell, John D Imig, James M Schmitz, John R Falck
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 70 Issue 4 Pg. 211-224 (Oct 2017) ISSN: 1533-4023 [Electronic] United States
PMID28937442 (Publication Type: Journal Article, Review)
Chemical References
  • Fatty Acids, Monounsaturated
  • 14,15-epoxy-5,8,11-eicosatrienoic acid
  • 8,11,14-Eicosatrienoic Acid
  • eicosenoic acid
Topics
  • 8,11,14-Eicosatrienoic Acid (administration & dosage, analogs & derivatives, chemistry)
  • Administration, Oral
  • Animals
  • Blood Pressure (drug effects, physiology)
  • Cardiovascular Diseases (drug therapy, physiopathology)
  • Fatty Acids, Monounsaturated (administration & dosage, chemistry)
  • Humans
  • Hypertension (drug therapy, physiopathology)
  • Kidney Diseases (drug therapy, physiopathology)
  • Muscle, Smooth, Vascular (drug effects, physiology)
  • Structure-Activity Relationship
  • Vasodilation (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: